SWM
CODX

SeaCrest Wealth Management’s Co-Diagnostics CODX Stock Holding History

SeaCrest Wealth Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-465
Closed -$270K – 592
2020
Q2 		$270K Buy
+465
New +$212K 0.05% 427

Other funds holding CODX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
IA
IFG Advisory Atlanta, Georgia $34.9M AUM 20.48% 1-Year Est. Return

SeaCrest Wealth Management's CODX Position: Q3 2020 in Review

SeaCrest Wealth Management sold out of Co-Diagnostics (CODX) in Q3 2020, closing a stake of 465 shares — an estimated $270K sold.

SeaCrest Wealth Management first reported a position in CODX in Q2 2020 and held it in 1 quarter. The position peaked at $270K in Q2 2020. 81 funds tracked by Wall St. Rank hold CODX as of Q3 2020.

  • SeaCrest Wealth Management reported no remaining Co-Diagnostics position as of Q3 2020 after selling out during the quarter.
  • SeaCrest Wealth Management sold 465 Co-Diagnostics shares in Q3 2020, an estimated $270K.
  • SeaCrest Wealth Management first reported a position in Co-Diagnostics in Q2 2020 and held it in 1 quarter.
  • SeaCrest Wealth Management's Co-Diagnostics position peaked at $270K in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2020.

Based on SeaCrest Wealth Management's 13F filing for Q3 2020, filed 12 Nov 2020.